GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Virbac SA (OTCPK:VRBCF) » Definitions » Debt-to-Revenue
中文

Virbac (Virbac) Debt-to-Revenue : 0.14 (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Virbac Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Virbac's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $85 Mil. Virbac's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $94 Mil. Virbac's annualized Revenue for the quarter that ended in Jun. 2023 was $1,323 Mil. Virbac's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 was 0.14.


Virbac Debt-to-Revenue Historical Data

The historical data trend for Virbac's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virbac Debt-to-Revenue Chart

Virbac Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 0.49 0.12 0.09 0.07

Virbac Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.09 0.12 0.08 0.14

Competitive Comparison of Virbac's Debt-to-Revenue

For the Drug Manufacturers - General subindustry, Virbac's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virbac's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Virbac's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Virbac's Debt-to-Revenue falls into.



Virbac Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Virbac's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(47.678 + 48.079) / 1288.334
=0.07

Virbac's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(85.166 + 94.496) / 1322.79
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2023) Revenue data.


Virbac Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Virbac's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Virbac (Virbac) Business Description

Traded in Other Exchanges
Address
2065m LID, 1 ere avenue, Carros, FRA, 06516
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, followed by North America and Latin America.

Virbac (Virbac) Headlines

From GuruFocus

Full Year 2020 Virbac SA Earnings Call Transcript

By GuruFocus Research 03-08-2024

Full Year 2022 Virbac SA Earnings Call Transcript

By GuruFocus Research 03-08-2024

Half Year 2019 Virbac SA Earnings Call Transcript

By GuruFocus Research 03-08-2024

Full Year 2021 Virbac SA Earnings Call Transcript

By GuruFocus Research 03-08-2024

Virbac SA SFAF Meeting Transcript

By GuruFocus Research 03-08-2024

Half Year 2021 Virbac SA Earnings Call Transcript

By GuruFocus Research 03-08-2024

Full Year 2018 Virbac SA Earnings Call Transcript

By GuruFocus Research 03-08-2024

Full Year 2019 Virbac SA Earnings Call Transcript

By GuruFocus Research 03-08-2024

Half Year 2022 Virbac SA Earnings Call Transcript

By GuruFocus Research 03-08-2024

Half Year 2020 Virbac SA Earnings Call Transcript

By GuruFocus Research 03-08-2024